Gestational Trophoblastic Disease: Diagnostic Workup and Treatment Protocol
For a reproductive-age woman with suspected gestational trophoblastic disease, immediately obtain serum β-hCG, perform pelvic ultrasound, and refer to a specialized GTD center for centralized care, pathology review, and hCG monitoring 1, 2.
Initial Diagnostic Workup
Essential First-Line Tests
- Serum β-hCG measurement: Critical for diagnosis and monitoring
- Pelvic ultrasound (Doppler preferred): Identifies characteristic "snowstorm" appearance of molar pregnancy, confirms absence of viable pregnancy, measures uterine size, and assesses tumor vasculature 1
- Complete blood count with differential and platelets
- Liver, renal, and thyroid function tests 3
- Blood type and Rh status: Essential for Anti-D prophylaxis planning
For Suspected Gestational Trophoblastic Neoplasia (GTN)
If hCG is elevated with clinical suspicion of malignancy, expand workup to include 1, 3:
- Contrast-enhanced CT chest/abdomen/pelvis (or MRI if contrast contraindicated)
- Brain MRI (preferred over CT) if pulmonary metastases are present
- Lumbar puncture for CSF-to-serum hCG ratio if CNS involvement suspected (ratio >1:60 suggests occult CNS disease)
Critical caveat: Do NOT biopsy visible lower genital tract lesions due to severe hemorrhage risk 3.
Management of Hydatidiform Mole
Primary Treatment
Perform suction dilation and curettage (D&C) for molar pregnancy evacuation 1. This is the standard approach for singleton molar pregnancies.
- Anti-D prophylaxis is mandatory following suction D&C of partial hydatidiform mole (PHM) 1
- Second D&C for persistent disease does NOT usually prevent subsequent chemotherapy need and should only be attempted after discussion with a GTD reference center 1
Post-Evacuation Surveillance Protocol
Monitor serum hCG every 1-2 weeks until three consecutive normal values are achieved 3. After normalization:
- Continue monthly hCG monitoring for 6 months minimum 3
- Some centers recommend lifelong monitoring given uncertainty about safe cessation timing 1
Diagnosis and Staging of GTN
Diagnostic Criteria for Post-Molar GTN
Chemotherapy is indicated when meeting any of the following 1, 3:
- hCG plateau for 4 consecutive values over 3 weeks
- hCG rise >10% for 3 consecutive values over 2 weeks
- hCG persistence ≥6 months after molar evacuation
- Serum hCG ≥20,000 IU/L at >4 weeks post-evacuation (uterine perforation risk)
- Heavy vaginal bleeding requiring transfusion
- Histological evidence of choriocarcinoma
- Metastases to brain, liver, or gastrointestinal tract
- Lung metastases >2 cm on chest X-ray
FIGO Staging and Risk Scoring
Apply the FIGO scoring system to determine treatment intensity 1:
- Stage I: Disease confined to uterus
- Stage II: Disease extends beyond uterus but limited to genital structures
- Stage III: Lung metastases
- Stage IV: All other metastatic sites
FIGO prognostic score incorporates: age, antecedent pregnancy type, interval from index pregnancy, pretreatment hCG level, largest tumor size, sites of metastases, number of metastases, and prior failed chemotherapy 1.
Important limitation: FIGO scoring is NOT valid for placental site trophoblastic tumor (PSTT) or epithelioid trophoblastic tumor (ETT) 1.
Treatment Protocols
Low-Risk GTN (FIGO Score 0-6)
Initiate single-agent chemotherapy with methotrexate plus folinic acid (MTX/FA) 1. This is preferred in most European centers because it is less toxic than MTX alone or actinomycin D (ActD), does not cause alopecia, and achieves nearly 100% cure rate even if first-line therapy fails 1.
Alternative acceptable regimen: Actinomycin D (ActD) 1
Continue chemotherapy for 6 weeks of maintenance treatment after hCG normalization 1.
Key point: Patients with scores 5-6 have higher drug resistance rates but overall survival still approaches 100% 4.
High-Risk GTN (FIGO Score ≥7)
Administer multi-agent chemotherapy with EMA/CO regimen (etoposide, methotrexate, actinomycin D alternating with cyclophosphamide and vincristine) 1. This is highly effective, simple to administer, and relatively non-toxic.
Extend maintenance therapy:
- Standard high-risk: 6 weeks after hCG normalization
- Poor prognostic features (liver ± brain metastases): 8 weeks after normalization 1
Ultra-High-Risk Disease
For patients with extensive tumor burden and risk of early death: Begin with induction low-dose etoposide and cisplatin before transitioning to standard therapy 1. Consider substituting EMA/CO with EP/EMA regimen 1.
PSTT/ETT Management
Treatment depends on stage and interval from last known pregnancy 1:
- Stage I disease presenting within 4 years: Hysterectomy with pelvic lymph node sampling
- Metastatic disease: Multi-agent chemotherapy (e.g., EP/EMA)
- Presenting beyond 4 years: Consider multi-agent followed by high-dose chemotherapy
Salvage Therapy for Treatment Failures
High-risk failures can be salvaged with EP/EMA or TE/TP regimens 1. Surgery alone can effectively salvage patients with isolated foci of chemoresistant disease 1.
Important: Residual lung or uterine masses following chemotherapy are NOT predictive of recurrence and do not require surgical excision 1.
Critical Management Principles
Centralization of Care
All GTN cases should be managed at specialized GTD centers with centralized pathology review and hCG monitoring 1, 2. This optimizes outcomes through:
- Expert multidisciplinary team discussions
- Standardized treatment protocols
- Long-term data collection for late effects monitoring
- Cross-border consultation for complex cases
Fertility Preservation
Fertility is preserved in 83% of women after MTX/FA or EMA/CO chemotherapy 1. There is no obvious increase in congenital malformations in subsequent pregnancies. When pregnancy occurs:
- Confirm normal pregnancy by ultrasound
- Discontinue follow-up during pregnancy
- Recheck hCG at 6 and 10 weeks postpartum to ensure no recurrence 1
Long-Term Monitoring
MTX therapy shows no significant increase in second tumors in over 15,000 patient-years of follow-up 1. For EMA/CO, there is no overall increased risk of second cancers, though a slight excess of leukemias exists with reduction in other cancers including breast cancer 1. Risk increases if combination chemotherapy continues beyond 6 months 1.
Common Pitfalls to Avoid
- Do not perform second D&C without GTD center consultation—it rarely prevents chemotherapy need 1
- Do not biopsy genital tract lesions—hemorrhage risk is prohibitive 3
- Do not assume elevated hCG equals GTN—consider phantom hCG (false positive from heterophile antibodies) 3
- Do not apply FIGO scoring to PSTT/ETT—these require different risk stratification 1
- Do not surgically excise residual masses after chemotherapy—they do not predict recurrence 1
This algorithmic approach ensures optimal outcomes with cure rates approaching 100% for low-risk disease and approximately 90% for high-risk disease when managed appropriately 4.